

 Low-energy electron machines

 1. Basic principles of X-ray production

 → bremsstrahlung

 → synchrotron radiation

 2. Physical, chemical and biological aspects of the application of electrons and bremsstrahlung photons

 3. Electron accelerators in medicine
 Gy - range

 4. Electron accelerators in industry
 kGy - range

 5. Electron storage rings for medicine and industry



## BEAM

- · well defined
- · variable in size
- moveable in three dimensions
- · variable energy
- · variable intensity
- X-ray ⇔ electron mode
- · pure and well-confined

#### TREATMENT UNIT

- · reliable and reproducible
- easy maneuvrable
- · simple and fail-safe
- very compact

WM/JUAS

3

Machine requirements							
energy range	4 - 25 MeV						
<ul> <li>intensity range</li> </ul>	0.5 - 50 μA						
• dose rates	1 - 4 Gy / min						
<ul> <li>number of electron energies</li> </ul>	5						
<ul> <li>number of X-ray energies</li> </ul>	2						
<ul> <li>homogeneity of X-ray fields</li> </ul>	5 % over 40 x 40 cm <sup>2</sup>						
<ul> <li>homogeneity of electron fields</li> </ul>	5 % over 25 x 25 cm <sup>2</sup>						
<ul> <li>leakage doses</li> </ul>	below 10 <sup>-3</sup> at 1 m						
<ul> <li>gantry rotation</li> </ul>	360°						
<ul> <li>isocentre definition</li> </ul>	1 mm						
<ul> <li>degrees of freedom</li> </ul>	15 (rotation and translation)						
<ul> <li>good definition at target</li> </ul>	energy, position, direction						
volume	5 x 3 x 3 m <sup>3</sup>						

# ion neid requirements

## DOSE RATE

- high
- irradiation time ~ 1/2 minute
- · accurately monitored
- fail-safe feedback to accelerator

### **DOSE DISTRIBUTION**

- uniform or
- · non-uniform in predefined way
- controllable
- · reproducible
- stable

WM







 Accelerating structures

 Energy:
 4 - 25 MeV

 Length:
 ~ 1 m

 HF power:
 2 - 5 MWp magnetron

 5 - 20 MWp klystron

Disc-loaded waveguides

























 Bending magnet systems
 TRANSPORT calculations

 WEAK FOCUSSING BENDING MAGNET
 Field index 0 < n < 1</td>

 Length L
 Bending angle  $\alpha$  Bending radius  $\rho$ 
 $M_{\rm H} = \begin{pmatrix} \cos\sqrt{1-n\alpha} & \frac{\rho\sin\sqrt{1-n\alpha}}{\sqrt{1-n\alpha}} & \frac{\rho(1-\cos\sqrt{1-n\alpha})}{1-n} \\ -\frac{\sqrt{1-n\sin\sqrt{1-n\alpha}}}{\rho} & \cos\sqrt{1-n\alpha} & \frac{\sin\sqrt{1-n\alpha}}{\sqrt{1-n}} \\ 0 & 0 & 1 \end{pmatrix}$ 
 $M_{\rm V} = \begin{pmatrix} \cos\sqrt{n\alpha} & \frac{\rho\sin\sqrt{n\alpha}}{\sqrt{n}} \\ -\frac{\sqrt{n\sin\sqrt{n\alpha}}}{\rho} & \cos\sqrt{n\alpha} \end{pmatrix}$ 













<figure>



















Medical radioisotope	Medical Isotope	Life- time T <sub>1/2</sub>	Use	Nuclear Reaction	Target Abun- dance (%)	Energy Range (MeV)	Production Yield (mCi @ sat)	Typical Dose (mCi)
•	11.0			11-22				
	"C	20.4m	PET	''B(p,n)	80.3	8 - 20	40/µA	-
	"C	20.4m	PET	<sup>1*</sup> N(p,α)	99.6	12	100/µA	
	+*C	20.4m	PET	<sup>10</sup> B(d,n)	19.7	7	10/µA	
Discussofic imaging	<sup>13</sup> N	9.96m	PET	<sup>13</sup> C(p,n)	1.1	5 - 10	115/µA	
Diagnostic imaging	<sup>13</sup> N	9.96m	PET	<sup>14</sup> C(d,n)	98.9	2-6	50/µA	
SDECT	<sup>13</sup> N	9.96m	PET	<sup>16</sup> O(p,α)	99.8	8 - 18	65/µA	
- OFLOT	100	2m	PET	<sup>15</sup> N(p,n)	0.36	10-15	47/µA	
- PFT	150	2m	PET	<sup>1</sup> °O(p,pn)	99.8	>26	25/µA	
. = .	150	2m	PET	<sup>14</sup> N(d,n)	99.6	8-6	27/µA	
	<sup>18</sup> F	109.8m	PET	<sup>18</sup> O(p,n)	0.20	8 - 17	180/µA	5 - 20
De all'a fle a van v	<sup>18</sup> F	109.8m	PET	<sup>20</sup> Ne(d, α)	90.5	2	82/µA	
Radiotherapy	<sup>64</sup> Cu	12.7h	SPECT	<sup>64</sup> Ni(p,n)	0.93	5 - 20	5/µA	
ß- emittere	<sup>67</sup> Cu	61.9h	SPECT	<sup>68</sup> Zn(p,2p)	19.0	>40	0.02/µA	
- p ennuers	<sup>67</sup> Ga	78.3h	SPECT	<sup>68</sup> Zn(p,2n)	19.0	20-40	4.5/µA	10
- $\alpha$ emitters	<sup>82</sup> Sr/ <sup>82m</sup> Rb	25d/5m	PET	<sup>85</sup> Rb(p,4n) <sup>82</sup> Sr Produces Rb	72.2	50 -70	0.18 /µAh	
	<sup>99m</sup> Tc	6h	SPECT	<sup>100</sup> Mo(p,2n)	9.7	19	14/µAh	20
	101 Pd	17.54	Therapy	Thi(p,n)	100	10-15	0.52/µAh	
	<sup>111</sup> In	67.2h	SPECT	<sup>112</sup> Cd(p,2n)	24.1	18 - 30	6/µAh	3
	123 I	13.2h	SPECT	<sup>124</sup> Xe(p,2n) <sup>123</sup> Cs → <sup>123</sup> Xe→ <sup>123</sup> I	0.10	25 - 35	27/µAh	
	<sup>123</sup> I	13.2h	SPECT	<sup>123</sup> Te(d,2n) <sup>123</sup> I	0.89	10-15	20/µAh	
	124I	4.1d	PET	<sup>124</sup> Te(p,n)	4.7	10 - 18	0.1/µAh	
	124I	4.1d	PET	<sup>124</sup> Te(d,2n)	4.7	>20	0.15/µAh	
	<sup>186</sup> Re	90.6h	Therapy /SPECT	<sup>186</sup> W(p,n)	28.4	18		
	<sup>201</sup> T1	73.5h	SPECT	<sup>203</sup> Tl(p,3n) <sup>201</sup> Pb → <sup>201</sup> Tl	29.5	27 - 35	0.7/µAh	4
	<sup>211</sup> At	7.2h	Therapy	<sup>209</sup> Bi(α,n)	100	28	l/μAh	0.05- .01











